These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Not reported||2006-003656-38||A Double-blind, Randomised, Parallel Groups Investigation into the Effects of Pregabalin, Duloxetine and Amitriptyline on Aspects of Pain, Sleep, and Next Day Performance in Patients Suffering from Di...||2009-05-12||due-trials|
|Completed, but no date||2006-006424-18||THE EFFECT OF RIMONABANT ON ENERGY EXPENDITURE, FATTY ACID METABOLISM, TRIACYLGLYCEROL METABOLISM AND BODY FAT DISTRIBUTION||bad-data|
|Ongoing||2007-003085-17||The effect of insulin detemir on energy balance, postprandial nutrient handling, body fat distribution,and adipose tissue metabolism and gene expression in patients with type 2 diabetes.||not-yet-due|
|Ongoing||2008-005363-34||Investigation to explore whether there is a synergistic effect between nicotine replacement therapy and guided bodyscanning on cigarette cravings and withdrawal symptoms in temporarily abstinent smoke...||not-yet-due|
|Not reported||2009-017806-36||Effect of Vitano® on physiological and psychological responses to psychological stress assessed under laboratory conditions and in everyday life.||2011-07-26||due-trials|
|Ongoing||2011-001642-14||The effects of subcutaneous insulin detemir on glucose flux, pharmacokinetics and brain function in type one diabetes||not-yet-due|
|Ongoing, reported early||2013-002826-22||The effect of Lixisenatide on triacylglycerol and glucose metabolism in patients with type 2 diabetes||not-yet-due|
|Ongoing||2014-002708-26||A randomised double blind placebo controlled pilot trial of oxytocin efficacy in treating detoxified opioid dependent individuals||not-yet-due|
|Ongoing||2015-002094-38||The Effect of an SGLT2 inhibitor on Glucose Flux, Lipolysis and Ketogenesis following insulin withdrawal in People with absolute or relative endogenous insulin deficiency||not-yet-due|